Biotech | April 09, 2026
Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Union Health Minister says India’s healthcare model blends traditional wisdom with modern science, backed by Ayushman Bharat and Janaushadhi expansion
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
Subscribe To Our Newsletter & Stay Updated
